Genomic Biomarkers Market: Growth Opportunities Through 2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Genomic Biomarkers Market Progress Between 2026 And 2030?

The genomic biomarkers market has seen significant growth in its size over recent years. It is anticipated to increase from $8.72 billion in 2025 to $10.24 billion in 2026, reflecting a compound annual growth rate (CAGR) of 17.5%. This historical expansion can be primarily attributed to advancements in genomic sequencing technologies, the expansion of oncology-focused biomarker research, the increasing adoption of personalized treatment approaches, improvements in clinical validation frameworks, and the rising availability of genomic databases.

The genomic biomarkers market is set for substantial growth over the coming years, with its valuation expected to reach $19.33 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 17.2%. This anticipated expansion during the forecast period is propelled by increasing investments in precision medicine programs, a rising demand for early disease detection tools, the expansion of biomarker-driven drug development, the growing integration of AI in biomarker analysis, and increasing regulatory support for personalized therapies. Significant trends shaping this period include the increasing adoption of biomarker-guided precision medicine, the rising integration of genomic data in clinical decision-making, a growing use of companion diagnostics, the expansion of multi-omics biomarker platforms, and an enhanced focus on clinical validation standards.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/genomic-biomarkers-global-market-report

What Key Factors Are Affecting The Genomic Biomarkers Market Demand?

The rising need for personalized medicine is projected to fuel the expansion of the genomic biomarkers market in the future. Personalized medicine, interchangeably called precision medicine, represents a healthcare strategy designed to customize medical choices and therapies according to each patient’s unique attributes, largely relying on their genetic and genomic data. This escalating requirement for personalized medicine stems from multiple elements, including the heightened focus on patient-focused care, advancements in genetic sequencing and analysis, a patient-centric methodology, and the utilization of EHRs for patient data storage and examination. Genomic biomarkers are instrumental in personalized medicine, allowing healthcare professionals to adapt medical therapies to an individual’s distinct genetic profile. This methodology, also termed precision medicine, endeavors to maximize treatment efficacy and reduce adverse reactions by taking into account the genetic variations among individuals. For example, in February 2024, the Personalized Medicine Coalition, a US-based professional membership organization, reported that in 2023, the FDA sanctioned 16 novel personalized therapies for rare disease patients, an increase from six in 2022. Consequently, the escalating need for personalized medicine propels the expansion of the genomic biomarkers market.

How Are Different Segments Classified In The Genomic Biomarkers Market Segment Analysis?

The genomic biomarkers market covered in this report is segmented –

1) By Type: Predictive Biomarkers, Prognostic Biomarkers

2) By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Other Disease Indications

3) By Validation: Analytical Validation, Clinical Validation, Clinical Utility

4) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By Predictive Biomarkers: Drug Response Biomarkers, Companion Diagnostics Biomarkers, Pharmacodynamic Biomarkers, Predictive Genetic Markers for Disease Susceptibility

2) By Prognostic Biomarkers: Cancer Prognostic Biomarkers, Cardiovascular Disease Prognostic Biomarkers, Neurodegenerative Disease Prognostic Biomarkers, Infectious Disease Prognostic Biomarkers

What Trends Are Influencing Changes In The Genomic Biomarkers Market?

Leading companies in the genomic biomarkers market are concentrating on creating innovative products, such as lung reagents, to improve the identification of specific genetic mutations in lung cancer, enhance diagnostic precision, and enable personalized treatment strategies by utilizing advanced genomic technologies. Lung reagents are specialized chemical or biological substances used in diagnostic tests, research, or medical procedures pertaining to the lungs, aiding precision medicine by guiding treatment choices based on the cancer’s unique genetic profile. For instance, in December 2023, Biofidelity, a UK-based company specializing in advanced genomic assays and precision diagnostics, introduced ASPYRE-Lung reagents. These ASPYRE-Lung reagents are developed to pinpoint key genetic mutations and alterations in lung cancer, which are essential for directing targeted therapies and individualized treatment plans.

Who Are The Companies Driving Activity In The Genomic Biomarkers Market?

Major companies operating in the genomic biomarkers market are Thermo Fisher Scientific Inc., Roche Diagnostics International Ltd., Illumina Inc., PerkinElmer Inc., Almac Group, Azenta Inc., Novogene Corporation, Oxford Nanopore Technologies Ltd., Celerion, Quanterix Corporation, Bio-Rad Laboratories Inc., NantHealth Inc., Centogene N.V., Sophia Genetics SA, Envisagenics, Deep Genomics, Creative Diagnostics, Macrogen Inc., Guardant Health Inc., Sema4

Get The Full Genomic Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/report/genomic-biomarkers-global-market-report

Where Is The Genomic Biomarkers Market Most Concentrated Geographically?

North America was the largest region in the genomic biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Genomic Biomarkers Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/genomic-biomarkers-global-market-report

Browse Through More Reports Similar to the Global Genomic Biomarkers Market 2026, By The Business Research Company

Digital Genome Market Report 2026

https://www.thebusinessresearchcompany.com/report/digital-genome-global-market-report

Single Cell Genome Sequencing Market Report 2026

https://www.thebusinessresearchcompany.com/report/single-cell-genome-sequencing-global-market-report

Whole Genome And Exome Sequencing Market Report 2026

https://www.thebusinessresearchcompany.com/report/whole-genome-and-exome-sequencing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795